DE69925279D1 - Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung - Google Patents

Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Info

Publication number
DE69925279D1
DE69925279D1 DE69925279T DE69925279T DE69925279D1 DE 69925279 D1 DE69925279 D1 DE 69925279D1 DE 69925279 T DE69925279 T DE 69925279T DE 69925279 T DE69925279 T DE 69925279T DE 69925279 D1 DE69925279 D1 DE 69925279D1
Authority
DE
Germany
Prior art keywords
sub
antibody
receptor
monoclonal antibody
csf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69925279T
Other languages
English (en)
Other versions
DE69925279T2 (de
Inventor
Angel Lopez
Andrea Richard D
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of DE69925279D1 publication Critical patent/DE69925279D1/de
Application granted granted Critical
Publication of DE69925279T2 publication Critical patent/DE69925279T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69925279T 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung Expired - Lifetime DE69925279T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPP525198 1998-08-13
AUPP5251A AUPP525198A0 (en) 1998-08-13 1998-08-13 Monoclonal antibody inhibitor of GM-CSF, IL-3 and IL-5 and other cytokines and uses thereof
PCT/AU1999/000659 WO2000009561A1 (en) 1998-08-13 1999-08-13 Monoclonal antibody inhibitor of gm-csf, il-3, il-5 and other cytokines, and uses thereof

Publications (2)

Publication Number Publication Date
DE69925279D1 true DE69925279D1 (de) 2005-06-16
DE69925279T2 DE69925279T2 (de) 2006-01-26

Family

ID=3809483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69925279T Expired - Lifetime DE69925279T2 (de) 1998-08-13 1999-08-13 Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung

Country Status (6)

Country Link
US (2) US6720155B1 (de)
EP (1) EP1105426B1 (de)
AT (1) ATE295376T1 (de)
AU (1) AUPP525198A0 (de)
DE (1) DE69925279T2 (de)
WO (1) WO2000009561A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US8197430B1 (en) 1998-05-22 2012-06-12 Biopheresis Technologies, Inc. Method and system to remove cytokine inhibitor in patients
CA2362264C (en) 1999-02-08 2012-05-08 Medvet Science Pty. Ltd. Cytokine-binding domain
US7108852B2 (en) * 2000-03-20 2006-09-19 Warner-Lambert Company Llc Methods of treating inflammation using antibodies to M-CSF
US8062637B2 (en) 2000-05-08 2011-11-22 Morphosys Ag Methods of ameliorating inflammatory disease using an uPA antagonist
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
AR045563A1 (es) * 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
PT1888643E (pt) * 2005-05-18 2015-01-14 Morphosys Ag Anticorpos anti-fec-gm e as respectivas utilizações
WO2008063898A2 (en) * 2006-11-08 2008-05-29 Kalobios Pharmaceuticals, Inc. Methods of treating idiopathic thrombocytopenia purpura using a gm-csf antagonist
US8398972B2 (en) 2006-11-21 2013-03-19 Kalobios Pharmaceuticals, Inc. Methods of treating dementia using a GM-CSF antagonist
US20100260744A1 (en) * 2007-07-11 2010-10-14 Medvet Science Pty Ltd. Regulating il-4 and il-13 levels by blocking high affinity binding by il-3, il-5 and gm-csf to their common receptor
GB0723179D0 (en) * 2007-11-27 2008-01-02 Immunovia Ab Diagnostic methods and arrays for use in the same
EP2193790A1 (de) * 2008-12-04 2010-06-09 Klinikum der Universität Regensburg IL-3-Inhibitoren zur Verwendung bei der Behandlung von rheumatoider Arthritis im Frühstadium
ES2886063T3 (es) 2008-12-22 2021-12-16 Univ Melbourne Tratamiento de la artrosis
RU2630969C2 (ru) 2008-12-22 2017-09-15 Де Юниверсити Оф Мельбурн Лечение боли
US20100209341A1 (en) 2009-02-18 2010-08-19 Csl Limited Treatment of chronic inflammatory conditions
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
JP6024025B2 (ja) 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
CA2874864C (en) 2012-08-14 2023-02-21 Ibc Pharmaceuticals, Inc. T-cell redirecting bispecific antibodies for treatment of disease
WO2017004144A1 (en) 2015-07-01 2017-01-05 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
PL2900277T3 (pl) 2012-12-13 2022-05-16 Immunomedics, Inc. Dawkowanie immunokoniugatów przeciwciał i sn-38 dla poprawy skuteczności i zmniejszenia toksyczności
WO2015126548A1 (en) 2014-02-21 2015-08-27 Ibc Pharmaceuticals, Inc. Disease therapy by inducing immune response to trop-2 expressing cells
WO2015130416A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
CA2953567C (en) 2014-06-24 2023-09-05 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
CN106999517A (zh) 2014-10-07 2017-08-01 免疫医疗公司 抗体‑药物缀合物的新辅助剂用途
JP6746845B2 (ja) 2015-04-22 2020-08-26 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． 循環ｔｒｏｐ−２陽性癌細胞の単離、検出、診断及び／または特徴付け
CN107735104B (zh) 2015-06-25 2022-05-03 免疫医疗公司 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善
AU2015406165A1 (en) * 2015-08-18 2018-03-15 Central Adelaide Local Health Network Inc. Novel cancer treatment involving modulation of IL-3 activity
CN108368167B (zh) 2015-11-27 2023-09-05 杰特有限公司 Cd131结合蛋白及其应用
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
EP4342497A1 (de) 2021-05-10 2024-03-27 Kawasaki Institute of Industrial Promotion Antikörper mit reduzierter bindungsaffinität für antigen
WO2023173173A1 (en) * 2022-03-16 2023-09-21 CSL Innovation Pty Ltd Method of treating an eosinophil-associated disease
WO2024081996A1 (en) * 2022-10-20 2024-04-25 CSL Innovation Pty Ltd Method of treating severe asthma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU706462B2 (en) * 1996-01-30 1999-06-17 Medvet Science Pty. Ltd. Cytokine antagonists and agonists
AUPN780096A0 (en) 1996-01-30 1996-02-22 Medvet Science Pty. Ltd. Cytokine antagonists and agonists

Also Published As

Publication number Publication date
US6720155B1 (en) 2004-04-13
DE69925279T2 (de) 2006-01-26
US20040265957A1 (en) 2004-12-30
EP1105426A4 (de) 2002-03-27
AUPP525198A0 (en) 1998-09-03
ATE295376T1 (de) 2005-05-15
WO2000009561A1 (en) 2000-02-24
US7427401B2 (en) 2008-09-23
EP1105426B1 (de) 2005-05-11
EP1105426A1 (de) 2001-06-13

Similar Documents

Publication Publication Date Title
DE69925279D1 (de) Monoklonaler antikörper als hemmstoff für gm-csf, il-3, il-5 und andere zytokine und deren verwendung
EP0176355A3 (de) Immunologisches Verfahren unabhängig von Antigenen
FR2844513B1 (fr) Anticorps pour adcc et induisant la production de cytokines.
ATE160379T1 (de) Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
DK473887A (da) Hybridomacellelinie, monoklonalt antistof, fremgangsmaade til fremstilling af og anvendelse af det monoklonale antistof
EP2336187B8 (de) Zusammensetzungen und Verfahren von monoklonalen oder polyklonalen Antikörpern, die spezifisch für T-Zell Subpopulationen sind
RO115415B1 (ro) Moleculă-3 de adeziune intercelulară (icam-3), moleculă adn recombinant care o codifică, anticorpi ai acesteia, metodă de producere a celulei hibridoma, metode de modulare a funcţiilor biologice, de suprimare, identificare, diagnoză şi compoziţii farmaceutice
NO2009012I1 (no) Humanisert anti-humant IL-6 reseptor monoklonalt antistoff
EP2186884A3 (de) Monoklonale Antikörpergegen HCV Kernantigen
ATE279443T1 (de) A3c6e2, ein monoklonaler antikörper spezifisch für den humanen stammzellfaktor (scf)-rezeptor
WO2002068646A3 (en) Mammalian cytokines; receptors; related reagents and methods
DE69933565D1 (de) Serinprotease-spzifischer moniklonaler antikörper und seine verwendung
ATE375802T1 (de) Ccr5 antikörper pa14
ATE217888T1 (de) Monoklonale antikörper gegen leukozyten- spezifische g-protein-gekoppelte rezeptoren
ATE58172T1 (de) Monoklonale antikoerper gegen alpha-2 interferon und hybridomas, die solche antikoerper produzieren.
SI1396501T1 (sl) Protitelesa za identifikacijo in/ali izolacijo najmanj ene celiäśne populacije, ki je izbrana iz skupine, ki obsega hematopoetske matiäśne celice, nevronske matiäśne celice, nevronske prekurzorske celice, mezenhimske matiäśne celice in mezenhimske pr
DE3576359D1 (de) Verfahren zur herstellung von tumorspezifische monoklonale antikoerper produzierenden hybridomazellen.
KR930701620A (ko) 재조합 dna 백터를 이용하여 인체 t-세포 리셉터 성분에 대한 단일 클론성 항체의 제조방법
Shinjo et al. Monoclonal anti-λ5 antibody FS1 identifies a 130 kDa protein associated with λ5 and Vpre-B on the surface of early pre-B cell lines
HK1041273B (zh) 產生代表特定細胞類型的單克隆抗體的組合物和方法
AU2003283240A1 (en) Antibody for isolating and/or identifying mesenchymal stem cells and method for isolating and/or identifying mesenchymal stem cells
Baran et al. Characterization of the soluble murine IL-2R and estimation of its affinity for IL-2.
SG54291A1 (en) Monoclonal antibodies to antigens expressed by hematopoietic facilitatory cells
ATE70311T1 (de) Monoklonale antikoerper gegen menschliche igerezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
DK1161522T3 (da) Fremgangsmåde til isolering af CD8+-celler og beslægtede hybridomaceller, antistoffer og polypeptider

Legal Events

Date Code Title Description
8364 No opposition during term of opposition